Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (101-110 of 191) with videos related to

Pageof 20
Sort By:
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
Human Vaccines & Immunotherapeutics|December 16, 2020
Safety and immunogenicity of an adjuvanted <i>Escherichia coli</i> adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 studyGary R Eldridge, Heidi Hughey, Lois Rosenberger, et al.
Urologic Oncology|October 7, 2023
Bladder cancer patient and provider perspectives on smoking cessationMatthew Mossanen, Angela B Smith, Nnamdi Onochie, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
BJU International|December 2, 2011
Testosterone in prostate cancer: the Bethesda consensusBob Djavan, James Eastham, Leonard Gomella, et al.
Urology|February 5, 2025
Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical PracticeNeal Shore, Andrew J Armstrong, Pedro Barata, et al.
Prostate Cancer and Prostatic Diseases|December 9, 2025
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE dataNeal Shore, Alicia K Morgans, Noman Paracha, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
Future Oncology (London, England)|May 19, 2021
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303Matthew D Galsky, Christopher J Hoimes, Andrea Necchi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
Pageof 20

Showing results (101-110 of 191) with videos related to

Sort By:
Pageof 20
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
Human Vaccines & Immunotherapeutics|December 16, 2020
Safety and immunogenicity of an adjuvanted <i>Escherichia coli</i> adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 studyGary R Eldridge, Heidi Hughey, Lois Rosenberger, et al.
Urologic Oncology|October 7, 2023
Bladder cancer patient and provider perspectives on smoking cessationMatthew Mossanen, Angela B Smith, Nnamdi Onochie, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
BJU International|December 2, 2011
Testosterone in prostate cancer: the Bethesda consensusBob Djavan, James Eastham, Leonard Gomella, et al.
Urology|February 5, 2025
Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical PracticeNeal Shore, Andrew J Armstrong, Pedro Barata, et al.
Prostate Cancer and Prostatic Diseases|December 9, 2025
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE dataNeal Shore, Alicia K Morgans, Noman Paracha, et al.
Future Oncology (London, England)|August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and researchDavid F Penson, Daniel W Lin, Lawrence Karsh, et al.
Future Oncology (London, England)|May 19, 2021
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303Matthew D Galsky, Christopher J Hoimes, Andrea Necchi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
Pageof 20